Aclaris Therapeutics, Inc.
Company Stats
- Market Cap
- $774.3M
- as of Sep 30, 2026
- Shares Outstanding
- 147.2M
- Free Float
- 67.1%
Income Statement
- Revenue
- $7.8M
- Operating Income
- -$76.4M
- Net Income
- -$64.9M
- EBITDA
- -$75.9M
- Revenue Growth, 3Y
- -35.9%
- FCF Margin, 3Y Avg
- -322.0%
- FCF Margin, Worst Year
- -603.4%
Cash Flow
- Free Cash Flow
- -$47.2M
- FCF Yield
- -6.1%
- Owner FCF Yield
- -7.7%
Balance Sheet
- Cash & Equivalents
- $20.0M
Returns & Capital
- SBC, 3Y Avg
- $14.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $7.8M | -$47.2M | -603.4% |
| FY2024 | $18.7M | -$20.2M | -107.9% |
| FY2023 | $31.2M | -$79.6M | -254.8% |
| FY2022 | $29.8M | -$68.2M | -229.1% |
| FY2021 | $6.8M | -$52.4M | -775.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 12, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back